On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. appeared on the Joe Rogan Experience (Episode #2461) and announced that approximately 14 of the 19 peptides on the FDA's Category 2 "do not compound" list would be moved back to Category 1 status.
This is the biggest regulatory shift in the peptide industry in years. But there's a gap between what was announced and what has actually changed — and that distinction matters if you're a patient, a clinician, or a vendor.
What Was Announced
Kennedy stated that approximately 14 peptides previously banned from compounding would be reclassified to Category 1, which would allow licensed compounding pharmacies to legally prepare them under a physician's prescription.
His stated rationale: restricting these compounds from legal compounding drives patients toward unregulated grey market vendors selling "research chemicals" of unknown quality. Moving them to Category 1 gives patients access through regulated, pharmacy-grade channels.
What Has NOT Changed (Yet)
This is the critical part. As of March 7, 2026:
- •No formal FDA rule has been published. No Federal Register notice has been issued removing any peptides from Category 2.
- •No statute has been amended.
- •The legal status of these peptides for compounding remains technically unchanged.
The announcement represents a stated policy intent from the HHS Secretary. Formal implementation requires the FDA to publish updated Category lists, which is expected to follow a comment period and review process.
Expected Timeline
- •February 27, 2026: HHS announcement (Kennedy on Joe Rogan)
- •March–April 2026: Expected 30-day comment period
- •May–June 2026: FDA finalizes technical requirements
- •July 2026+: State pharmacy boards begin implementing local rules
The 14 Peptides Expected to Move to Category 1
Based on multiple sources reporting on the announcement, these peptides are expected to be reclassified:
| Peptide | Primary Use |
|---|---|
| BPC-157 | Tissue repair, gut healing |
| Thymosin Beta-4 (TB-500) | Wound healing, recovery |
| Thymosin Alpha-1 | Immune modulation |
| GHK-Cu | Skin rejuvenation, anti-aging |
| AOD-9604 | Fat metabolism |
| MOTS-C | Metabolic regulation |
| Epitalon | Telomere support, longevity |
| KPV | Anti-inflammatory, gut health |
| Semax | Cognitive enhancement |
| Selank | Anxiolytic, immune support |
| Kisspeptin-10 | Hormone regulation |
| DSIP (Emideltide) | Sleep regulation |
Note: The official FDA list of all 14 has not been formally published. Some sources include additional peptides (PT-141, Ipamorelin, CJC-1295) while others place those in different categories. We will update this list when the formal FDA reclassification is published.
Important: Five peptides were already removed from Category 2 in September 2024 (AOD-9604, CJC-1295, Ipamorelin, Thymosin Alpha-1, and Selank) when their nominators withdrew the nominations. These were then referred to the Pharmacy Compounding Advisory Committee (PCAC) for further review.
The ~5 Peptides Expected to REMAIN Restricted
Approximately 5 peptides are expected to stay on the Category 2 list due to documented safety concerns:
| Peptide | Safety Concern |
|---|---|
| Melanotan II | Cardiovascular risks, melanoma concerns |
| GHRP-2 | Adverse events including deaths, cortisol/prolactin elevation |
| GHRP-6 | Similar safety profile to GHRP-2 |
| Cathelicidin LL-37 | Limited human safety data |
| PEG-MGF | Insufficient clinical evidence |
The FDA has documented adverse events — including deaths — linked to GHRP-2, which is a significant factor in its continued restriction.
What Category 1 Actually Means
Moving to Category 1 does NOT mean FDA approval. Here's what it does and doesn't mean:
It means: - Licensed compounding pharmacies (503A and 503B) can legally prepare these peptides - A valid physician prescription is required - Pharmacies must comply with USP compounding standards - Compounds must meet purity, potency, and sterility requirements
It does NOT mean: - FDA-approved for any indication - Available over the counter - Covered by insurance (unlikely in the near term) - That grey market "research chemical" vendors are now legal
The Political Context
This announcement didn't happen in a vacuum. The political and industry pressure was significant:
- •November 2025: Rep. Diana Harshbarger (R-TN), a pharmacist, sent a letter to Secretary Kennedy asking HHS to exercise enforcement discretion on peptides including BPC-157 and to reevaluate Category 2 restrictions.
- •Senator Tommy Tuberville (R-AL) made similar requests.
- •The Alliance for Pharmacy Compounding (A4PC) has been lobbying for reclassification, arguing that banning compounding drives patients to unregulated sources.
- •Legal challenges: The compounding industry has argued the FDA lacked the required safety signal to justify placing these peptides on the restricted list.
Critics, including stem cell biologist Paul Knoepfler and others, argue that most of these peptides lack sufficient human clinical trial data and that loosening restrictions could expose patients to risks.
What This Means for You
If you currently buy from research vendors:
The grey market is not suddenly safer. These regulatory changes specifically benefit the *prescribed* compounding pathway — not the "research use only" vendor model. In fact, as legal compounding expands, regulatory pressure on grey market vendors is likely to increase, not decrease. The shutdown of Peptide Sciences in March 2026 is evidence of this trend.
If you want prescribed peptides:
This is very good news. Once the formal reclassification happens, telehealth clinics and your doctor can prescribe compounds like BPC-157, TB-500, and GHK-Cu, and your pharmacy can legally compound them. Prices should decrease as supply expands through legitimate channels.
If you're a clinician:
Wait for the formal FDA publication before prescribing compounds still technically on Category 2. The announcement signals intent, but until the list is formally updated, the legal risk remains.
PeptideVerdict's Position
We're tracking this closely and will update this article as the formal FDA reclassification is published. We're also expanding our coverage to include telehealth peptide clinics — because the future of peptide access is prescribed, not grey market.
We believe this shift is ultimately positive for patients: access to pharmacy-grade peptides with medical oversight is safer than the "research chemical" model, period. But we also believe in accuracy over hype — and right now, the formal rule hasn't been published yet. We'll call it what it is, not what we wish it were.
This article reflects information available as of March 7, 2026. It will be updated as the formal FDA reclassification is published. Sources include FDA.gov, the HHS announcement, congressional records, and legal analysis from Holt Law, LumaLex Law, and Frier Levitt.